Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.